

### Margins to expand beyond Cx sale

We attended the GSK Pharma analyst meet. The management highlighted that the ongoing global specialty focus by Plc would enable India share of specialty going up over the coming decade. The recent launch pipeline holds *Shingrix*, *Trelegy*, indication expansion for *Nucala* and *Fluarix Tetra*. The management is confident on *Nucala* upcoming expansion given the patient reach expansion by 4x. Considering the healthy launch pipeline, the management is confident of expanding EBITDA margins beyond the Cx transaction. Valued at 16x EBITDA and 6x Sales, closure is expected in FY22E. We have adjusted for near-term EBITDA impact (1-1.5%) by reducing estimates by 4.5% for FY23E. Maintain BUY. We are optimistic on future pipeline including Covid vaccine.

#### Vaccine availability could be on fast track if trial results favorable

Globally, the GSK group is working with Sanofi and Medicago to harness the adjuvant technology in developing Covid-19 vaccines while also collaborating with CureVac to develop mRNA vaccines that have the potential to address multiple Covid-19 variants that are emerging across the world. Sanofi is conducting phase 3 trial in India; post the trials completion, GSK would be able to share more details.

#### Management believes Cx transaction is fairly valued

GSK India entered into an agreement GSK Asia (consumer arm of GSK plc) to sell *Iodex* and *Ostocalcium* brands (Cx) for Rs16.49bn, valued at 16x EBITDA / 6x sales. Management believes valuation is fair, as GSK only owned the distribution rights for the brands. This Cx transaction would impact the EBITDA for FY23 by ~Rs1bn.

#### Core brands and vaccines to drive growth

The key focus brands under pharma account for ~70% of revenue and have registered a growth of 14% in the last five years. The management expects this trend to continue for the pharma segment. The vaccine business grew at ~10% CAGR over the last five years and is expected to grow faster ahead, with new vaccine additions. According to the guidance provided, vaccine margins would be ~9-10%, largely considered as distribution margins. We believe if core Pharma brands continue to grow at mid-double digits, then EBITDA margin expansion with some support from operating leverage should allow margin expansion beyond Cx transaction.

#### Valuation and risks

The management strategy is to drive growth by following the three pillar approach: Grow, Build and Shred. The top-20 focus brands continue to be key growth drivers. Building new specialty brands (parent's pipeline) would enable room for focused growth. We expect 2-3 innovative product launches in India in the coming fiscal, followed by oncology pipeline. The management focus on improving cost efficiency should be earnings accretive. The divestment of two brands has come at much better valuation post the Vemgal asset sale. We have increased the valuation multiple for GSK to 41x FY23E and arrive at a TP of Rs1,805. At CMP of Rs1,575, the stock trades at 42x FY22E EPS of Rs37.5 and 36.1x FY23E EPS of Rs43.6. Maintain BUY.

#### Financial and valuation summary

| YE Mar (Rs mn)    | FY19A  | FY20A  | FY21A  | FY22E  | FY23E  |
|-------------------|--------|--------|--------|--------|--------|
| Revenues          | 31,285 | 32,244 | 31,989 | 35,088 | 38,449 |
| EBITDA            | 6,026  | 6,611  | 6,953  | 8,143  | 8,924  |
| EBITDA margin (%) | 19.3   | 20.5   | 21.7   | 23.2   | 23.2   |
| Adj. Net profit   | 4,171  | 4,606  | 5,343  | 6,367  | 7,415  |
| Adj. EPS (Rs)     | 24.5   | 27.1   | 31.4   | 37.5   | 43.6   |
| EPS growth (%)    | 24.4   | 10.4   | 16.0   | 19.2   | 16.5   |
| PE (x)            | 64.9   | 58.8   | 50.7   | 42.5   | 36.5   |
| EV/EBITDA (x)     | 43.5   | 39.7   | 37.7   | 32.2   | 29.2   |
| PBV (x)           | 6.3    | 7.4    | 9.0    | 7.8    | 7.3    |
| RoE (%)           | 19.9   | 23.3   | 32.2   | 39.4   | 41.3   |
| RoCE (%)          | 17.4   | 20.4   | 27.5   | 33.2   | 34.7   |

Source: Bloomberg, Centrum Broking

#### Company Update

India I Pharmaceuticals

18 August, 2021

**BUY**

Price: Rs1,575

Target Price: Rs1,805

Forecast return: 15%

Institutional Research

#### Market Data

|                       |             |
|-----------------------|-------------|
| Bloomberg:            | GLXO IN     |
| 52 week H/L:          | 1,808/1,376 |
| Market cap:           | Rs266.8bn   |
| Shares Outstanding:   | 169.4mn     |
| Free float:           | 18.6%       |
| Avg. daily vol. 3mth: | 76,396      |


Source: Bloomberg

#### Changes in the report

|               |                          |
|---------------|--------------------------|
| Rating:       | Unchanged at BUY         |
| Target price: | Changed to Rs.1,800      |
| EPS:          | +1.5% FY22E, -1.7% FY23E |

Source: Centrum Broking

#### GLXO relative to Nifty 50



Source: Bloomberg

#### Shareholding pattern

|              | Jun-21 | Mar-21 | Dec-20 | Sep-20 |
|--------------|--------|--------|--------|--------|
| Promoter     | 75.0   | 75.0   | 75.0   | 75.0   |
| FII's        | 1.6    | 1.6    | 1.5    | 1.0    |
| DII's        | 5.5    | 5.3    | 5.3    | 5.7    |
| Public/other | 17.9   | 18.1   | 18.2   | 18.3   |

Source: BSE



**Cyndrella Carvalho**

Analyst, Pharmaceuticals

+91-22-4215 9643

cyndrella.carvalho@centrum.co.in

Pharmaceuticals

# Thesis Snapshot

## Estimate revision

| YE Mar (Rs mn)   | FY22E<br>New | FY22E<br>Old | % chg  | FY23E<br>New | FY23E<br>Old | % chg   |
|------------------|--------------|--------------|--------|--------------|--------------|---------|
| Revenue          | 35,532       | 34,913       | 1.8    | 38,449       | 39,215       | -2.0    |
| EBITDA           | 8,232        | 8,126        | 1.3    | 8,953        | 9,780        | -8.5    |
| EBITDA margin    | 23.2%        | 23.3%        | -10bps | 23.3%        | 24.9%        | -165bps |
| Adj. PAT         | 6,382        | 6,285        | 1.5    | 7,415        | 7,762        | -4.5    |
| Diluted EPS (Rs) | 37.7         | 37.1         |        | 43.6         | 45.8         |         |

Source: Centrum Broking

## GSK versus NIFTY 50

|          | 1m    | 6m   | 1 year |
|----------|-------|------|--------|
| GLXO IN  | (0.1) | 9.4  | 4.8    |
| NIFTY 50 | 5.2   | 10.6 | 45.2   |

Source: Bloomberg, NSE

## Key assumptions

| Y/E Mar           | FY22E | FY23E |
|-------------------|-------|-------|
| Revenue growth %  | 11.1  | 8.2   |
| Material cost (%) | 41.3  | 40.7  |


Source: Centrum Broking

## Valuations


We have increased the valuation multiple for GSK to 41x FY23E and arrive at a TP of Rs1,800. At CMP of Rs1,575, the stock trades at 42x FY22E EPS of Rs37.5 and 36.1x FY23E EPS of Rs43.6. Maintain BUY.

| Valuations          | Rs/share |
|---------------------|----------|
| FY23E PE (x)        | 36.1     |
| FY23E Adj EPS (Rs.) | 43.6     |

### P/E mean and standard deviation



### EV/EBITDA mean and standard deviation



Source: Bloomberg, Centrum Broking

## Peer comparison

| Company | Mkt Cap | CAGR (FY21-23E) |        |      | P/E (x) |       |       | EV/EBITDA (x) |       |       | ROE (%) |       |       |
|---------|---------|-----------------|--------|------|---------|-------|-------|---------------|-------|-------|---------|-------|-------|
|         | (Rs mn) | Sales           | EBITDA | PAT  | FY21    | FY22E | FY23E | FY21          | FY22E | FY23E | FY21    | FY22E | FY23E |
| GLXO    | 266,975 | 9.6             | 13.5   | 17.8 | 50.1    | 42.0  | 36.1  | 8.9           | 7.7   | 9.9   | 32.2    | 39.5  | 48.1  |
| BOOT    | 400,762 | 15.5            | 23.7   | 27.4 | 58.6    | 43.1  | 36.0  | 41.3          | 32.1  | 26.6  | 27.2    | 33.0  | 33.8  |
| SNAL    | 205,097 | 4.7             | 11.5   | 16.3 | 39.4    | 32.6  | 29.1  | 28.7          | 24.6  | 23.1  | 28.1    | 29.1  | 27.3  |
| PFIZ    | 268,994 | 12.8            | 14.5   | 21.1 | 54.1    | 39.7  | 36.9  | 36.2          | 28.6  | 26.7  | 17.2    | 27.8  | 26.8  |

Source: Company, Centrum Broking

## Key takeaways from Analyst Meet

- Sale of *Iodex* and *Ostocalcium* brands (Cx) valued at 16x EBITDA (6x sales) for Rs16.49bn. While GSK India doesn't own these brands, valuation may seem low. This transaction is expected to normalize tax rate still under discussion. It would impact near-term EBITDA margins by 1-1.5%, but the company is confident of growing the margins beyond this transaction.
- The management would be working on better utilization of this cash and is currently looking at all possible options.
- Globally, the GSK group is working with Sanofi and Medicago to harness the adjuvant technology in developing Covid-19 vaccines while also collaborating with CureVac to develop mRNA vaccines that have the potential to address multiple Covid-19 variants that are emerging across the world. Sanofi is conducting phase 3 trial in India; post the trials completion, GSK would share more details.
- Specialty brands will be launched in the 2nd-3rd phase of expansion (Zejula and other oncology assets acquisition of Tesaro) over the coming 2-3 years. As of now, the company has *Nucala* as the only specialty asset as a part of revenues.
- *Nucala* sales are expected to grow 5x in H2FY22 over H1FY20 (4x patient growth).
- Other near-term applications include *Benlysta*, indication expansion for Vaccine *Fluarix* tetra – for the use in adults above 64 years, *Shingrix* - for prevention of Herpes Zoster and Post-Herpetic Neuralgia in adults aged ≥50 years, *Trelegy*, Phase 3 study for - RSV Maternal (RSVPreF3) vaccine in India.
- The company launched brand extension, *Augmentin ES* and *Neosporine* 10mg.
- Key focus pharma brands account for ~70% of revenue and grew at 14-15% in the last five years. The company anticipates the same growth, going ahead. Growth for the rest of the pharma portfolio was flat to negative in the same period.
- Vaccine business grew at ~10% in last five years, and is expected to grow faster ahead with near-term launch of *Shingrix* Vaccine.
- The company's focus is on fixed cost reduction and over the coming 2-3 years, EBITDA margins are expected to be ~24% (ex-consumer brands).
- Vaccine margins at 9-10% are largely considered as distribution margins.
- In-house and CMO manufacturing split stood at 35-65% in FY21.
- The company does not see any re-launch opportunity for *Ranitidine*.
- The company ranks 1st in vaccine and derma segment.
- Currently, 24% of portfolio is under NELM. Management has taken nearly 5% price hike in this fiscal.
- Semi-urban and rural markets are growing faster than “big towns” and the management expects this trend to continue post Covid, as well.

### Exhibit 1: Revenue break up

|               | FY17         | FY18         | FY19         | FY20         | FY21         | CAGR        |
|---------------|--------------|--------------|--------------|--------------|--------------|-------------|
| Vaccine       | 514          | 478          | 629          | 679          | 762          | 10.3        |
| % of sales    | 21.8         | 19.6         | 22.5         | 22.2         | 24.3         |             |
| Consumer      | 213          | 188          | 226          | 243          | 274          | 6.5         |
| % of sales    | 9.0          | 7.7          | 8.1          | 7.9          | 8.7          |             |
| Pharma        | 1,633        | 1,776        | 1,939        | 2,138        | 2,096        | 6.4         |
| % of sales    | 69.2         | 72.7         | 69.4         | 69.9         | 66.9         |             |
| <b>Total</b>  | <b>2,360</b> | <b>2,442</b> | <b>2,794</b> | <b>3,060</b> | <b>3,132</b> | <b>7.3</b>  |
| <b>EBITDA</b> | <b>420</b>   | <b>510</b>   | <b>631</b>   | <b>638</b>   | <b>695</b>   | <b>13.4</b> |
| EBITDA margin | 14.0         | 18.0         | 20.0         | 21.0         | 22.0         |             |

Source: Company, Centrum Broking

# Highlights from AR 2020-2021

## Management Discussion and Analysis

### Finance and Accounts

- Despite Covid, the Company not only maintained but successfully consolidated its market position during the year. Its market share in represented segments increased, while key established brands quickly bounced back to double-digit growth.
- At Rs31.9bn, revenue from operations declined 1%.
- Despite the detrimental impact of Covid-19 on operations for the year, the company registered an underlying sales growth of 3%, driven by sustained focus on key brands and appropriate rationalization of tail-end brands. Other income was higher on account of Rs710mn in interest on refunds from the income tax authorities.
- Exceptional charges during the year, amounting to Rs1.7bn largely comprise impairment charge to reflect the estimated realizable value of assets, reversal of associated costs and of earlier provisions no longer required on account of the Zinetac recall. Profit before exceptional items and tax amounted to Rs7.2bn, at 23% of sales for the year.

## Business Performance and Outlook

### Pharmaceuticals

- Amid the lockdown, GSK's field force remained active on the ground, using digital channels effectively to engage remotely with Health Care Professionals (HCPs).
- GSK reached 30 million touch points through its robust digital infrastructure such as enhanced use of tele-calling, webinars and emailers, coupled with adoption of state-of-the-art technology platforms such as Veeva Engage.

### Vaccines

- GSK delivered 0.9 billion packs of medicines and over 5.1 million vaccine doses (IQVIA March 2021 dataset).
- The company added two vaccines in the Flu category.
- The self-pay vaccines market is estimated to be over Rs25bn. It is currently not reflecting any value growth (IMS MAT March 2021) on account of the slower uptake of vaccination during the Covid-19 related lockdowns.
- GSK currently markets 10 vaccines across age groups.
- In September 2020, the company launched tetravalent influenza northern hemisphere vaccine (Fluarix Tetra NH 2020-21) to combat influenza. Within three months of the launch, the vaccine had garnered 30% volume share in the market.
- GSK plc, the parent company, entered into an in-principle global partnership with Novavax to produce up to 60 million doses of the Covid-19 vaccine.
- It is also working with Sanofi and Medicago to harness the adjuvant technology in developing Covid-19 vaccines.
- Collaborating with CureVac to develop mRNA vaccines that have the potential to address multiple Covid-19 variants emerging across the world.

### Regulatory Affairs

- The company applied to Central Drugs Standard Control Organization (CDSCO) for registration of
- Herpes Zoster Vaccine [Shingrix] for prevention of Herpes Zoster and Post-Herpetic Neuralgia in adults aged ≥50 years
- Belimumab Solution for Injection 200mg/ml [Benlysta] for treatment of adults with systemic Lupus Erythematosus and Lupus Nephritis

- Indication expansion for Quadrivalent Inactivated Influenza Vaccine (Fluarix tetra) for use in adults over 64 years of age.
- Applications were made for registration of
  - a new fixed dose combination of Fluticasone Furoate, Umeclidinium and Vilanterol Powder for Inhalation (Trelegy) for chronic obstructive pulmonary disease
  - new strength of an already marketed oral suspension of Augmentin viz. Amoxicillin and Potassium Clavulanate oral suspension 642.9 mg/5ml (Augmentin ES)
  - a ready-to-use liquid formulation of Mepolizumab Injection 100mg (Nucala) for treatment of severe refractory eosinophilic asthma in adults.
- A Global Clinical Trial (GCT) application was approved during the year, for conducting a multi-country phase 3 study with Respiratory Syncytial Virus (RSV) Maternal (RSVPreF3) vaccine in India.

### **Dividends**

- Directors recommended a dividend of Rs30 per equity share and will absorb Rs5.08bn.

### **Related Party Transactions**

- All related party transactions entered during the year were on arm's length basis and were in ordinary course of business. There were no materially significant related party transactions made with the promoters, directors or key managerial personnel that may have a potential conflict of interest with GSK India at large.

### **Vemgal Update**

- During FY21, GSK charged Rs1.73bn as exceptional charges, largely comprising of impairment charge to reflect the estimated realizable value of the assets, reversal of associated costs and of earlier provisions no longer required on account of the Zinetac recall.
- In Q4, GSK entered into a binding agreement for the sale of Vemgal assets to Hetro Labs. The conclusion of this sale is subject to necessary statutory and regulatory approvals.
- A deposit of Rs1.8bn was received towards the sale of Vemgal assets.

### **Opportunities, risks, concern and threats**

- Several experts have predicted that India may experience future waves of Covid-19, which could further stretch the country's healthcare ecosystem. This may also impact GSK India's ability to service its patients and HCPs on time.
- The outbreak of the global pandemic has also created raw material (Active Pharmaceuticals Ingredients or APIs) related disruptions for the Indian pharmaceutical industry.
- The revised National List of Essential Medicines (NLEM) is expected to be released by the Government later in 2021. The company is engaging in various stakeholder discussions on NLEM.
- The healthcare policy landscape in India is at an inflection point. Amid the pandemic, the uptake and acceptance of new areas of healthcare delivery, such as telemedicine, e-pharmacies, Over-the-Counter (OTC) medicines, are at an all-time high. New Government regulations could redefine the healthcare sector in the long term, and GSK is in discussions with policymakers and stakeholders on the subject.

### **MD Speech Highlights**

- During FY21, GSK delivered 0.9 billion packs of medicines and over 5.1 million vaccine doses (IQVIA March 2021 dataset). This was even more exceptional considering the current challenging times we were all going through and were concerned about the safety and wellbeing of our families and loved ones.
- Notwithstanding the challenges posed by disrupted supply chains and production lines due to the pandemic, GLXO adopted tireless efforts to keep the operations up and

running. Its manufacturing facilities and workplaces attempted their best to ensure that our manufacturing and distribution networks operated at full capacity.

- GSK's foresight in adopting digital transformation and consolidating its reach through multi-channel marketing helped us connect with Health Care Professionals (HCPs) remotely and expand our touchpoints on a variety of platforms. This leveraged to build on partnerships with leading professional healthcare bodies. Helping GSK to drive engagement on several initiatives that included appropriate administering and usage of antibiotics in the wake of COVID-19 and anti-microbial resistance (AMR).
- GSK plc, the parent company, entered into an in-principle global partnership with Novavax to produce up to 60 million doses of the Covid-19 vaccine and is also working with Sanofi and Medicago to harness the adjuvant technology in developing Covid-19 vaccines while also collaborating with CureVac to develop mRNA vaccines which have the potential to address multiple Covid-19 variants that are emerging across the world.
- FY 2021-22 is expected to be a promising year. The board remains set to introduce new assets during the next year to reiterate the company's position as a science and innovation-led pharmaceutical major.

| P&L                            |               |               |               |               |               |
|--------------------------------|---------------|---------------|---------------|---------------|---------------|
| YE Mar (Rs mn)                 | FY19A         | FY20A         | FY21A         | FY22E         | FY23E         |
| <b>Revenues</b>                | <b>31,285</b> | <b>32,244</b> | <b>31,989</b> | <b>35,088</b> | <b>38,449</b> |
| Operating Expense              | 16,620        | 16,298        | 15,514        | 17,911        | 19,509        |
| Employee cost                  | 5,372         | 6,286         | 6,147         | 6,404         | 6,729         |
| Others                         | 3,281         | 3,088         | 3,374         | 2,631         | 3,287         |
| <b>EBITDA</b>                  | <b>6,026</b>  | <b>6,611</b>  | <b>6,953</b>  | <b>8,143</b>  | <b>8,924</b>  |
| Depreciation & Amortisation    | 486           | 827           | 793           | 591           | 606           |
| <b>EBIT</b>                    | <b>5,540</b>  | <b>5,784</b>  | <b>6,161</b>  | <b>7,552</b>  | <b>8,318</b>  |
| Interest expenses              | 6             | 63            | 0             | 0             | 0             |
| Other income                   | 1,009         | 762           | 1,106         | 1,087         | 1,648         |
| <b>PBT</b>                     | <b>6,544</b>  | <b>6,483</b>  | <b>7,266</b>  | <b>8,639</b>  | <b>9,966</b>  |
| Taxes                          | 2,373         | 1,877         | 1,924         | 2,272         | 2,551         |
| Effective tax rate (%)         | 36.3          | 29.0          | 26.5          | 26.3          | 25.6          |
| <b>PAT</b>                     | <b>4,171</b>  | <b>4,606</b>  | <b>5,343</b>  | <b>6,367</b>  | <b>7,415</b>  |
| Minority/Associates            | 0             | 0             | 0             | 0             | 0             |
| <b>Recurring PAT</b>           | <b>4,171</b>  | <b>4,606</b>  | <b>5,343</b>  | <b>6,367</b>  | <b>7,415</b>  |
| Extraordinary items            | 287           | (3,415)       | (1,726)       | 0             | 13,192        |
| <b>Reported PAT</b>            | <b>4,458</b>  | <b>1,191</b>  | <b>3,617</b>  | <b>6,367</b>  | <b>20,607</b> |
| Ratios                         |               |               |               |               |               |
| YE Mar                         | FY19A         | FY20A         | FY21A         | FY22E         | FY23E         |
| <b>Growth (%)</b>              |               |               |               |               |               |
| Revenue                        | 8.0           | 3.1           | (0.8)         | 9.7           | 9.6           |
| EBITDA                         | 18.6          | 9.7           | 5.2           | 17.1          | 9.6           |
| Adj. EPS                       | 24.4          | 10.4          | 16.0          | 19.2          | 16.5          |
| <b>Margins (%)</b>             |               |               |               |               |               |
| Gross                          | 56.6          | 59.6          | 59.0          | 58.8          | 59.3          |
| EBITDA                         | 19.3          | 20.5          | 21.7          | 23.2          | 23.2          |
| EBIT                           | 17.7          | 17.9          | 19.3          | 21.5          | 21.6          |
| Adjusted PAT                   | 13.3          | 14.3          | 16.7          | 18.1          | 53.6          |
| <b>Returns (%)</b>             |               |               |               |               |               |
| ROE                            | 19.9          | 23.3          | 32.2          | 39.4          | 41.3          |
| ROCE                           | 17.4          | 20.4          | 27.5          | 33.2          | 34.7          |
| ROIC                           | 30.2          | 35.5          | 54.9          | 63.3          | 71.2          |
| <b>Turnover (days)</b>         |               |               |               |               |               |
| Gross block turnover ratio (x) | 6.5           | 4.0           | 7.4           | 8.0           | 8.3           |
| Debtors                        | 16            | 12            | 18            | 17            | 11            |
| Inventory                      | 133           | 135           | 143           | 98            | 56            |
| Creditors                      | 122           | 107           | 114           | 99            | 80            |
| Net working capital            | 65            | 85            | 99            | 112           | 114           |
| <b>Solvency (x)</b>            |               |               |               |               |               |
| Net debt-equity                | (0.4)         | (0.4)         | (0.6)         | (0.5)         | (0.5)         |
| Interest coverage ratio        | 1,087.2       | 104.9         | 0.0           | 0.0           | 0.0           |
| Net debt/EBITDA                | (1.4)         | (1.2)         | (1.3)         | (1.0)         | (1.1)         |
| <b>Per share (Rs)</b>          |               |               |               |               |               |
| Adjusted EPS                   | 24.5          | 27.1          | 31.4          | 37.5          | 43.6          |
| BVPS                           | 251.7         | 214.2         | 176.4         | 203.4         | 218.6         |
| CEPS                           | 54.8          | 63.9          | 72.2          | 81.9          | 94.4          |
| DPS                            | 39.9          | 79.7          | 59.8          | 39.9          | 189.3         |
| Dividend payout (%)            | 76.0          | 569.0         | 140.5         | 53.2          | 78.1          |
| <b>Valuation (x)</b>           |               |               |               |               |               |
| P/E                            | 64.9          | 58.8          | 50.7          | 42.5          | 36.5          |
| P/BV                           | 6.3           | 7.4           | 9.0           | 7.8           | 7.3           |
| EV/EBITDA                      | 43.5          | 39.7          | 37.7          | 32.2          | 29.2          |
| Dividend yield (%)             | 2.5           | 5.0           | 3.8           | 2.5           | 11.9          |

Source: Company, Centrum Broking

| Balance sheet                   |                |                |                |                |                 |
|---------------------------------|----------------|----------------|----------------|----------------|-----------------|
| YE Mar (Rs mn)                  | FY19A          | FY20A          | FY21A          | FY22E          | FY23E           |
| Equity share capital            | 1,694          | 1,694          | 1,694          | 1,694          | 1,694           |
| Reserves & surplus              | 19,704         | 16,512         | 13,304         | 15,604         | 16,898          |
| Shareholders fund               | 21,398         | 18,206         | 14,991         | 17,292         | 18,585          |
| Minority Interest               | 0              | 0              | 0              | 0              | 0               |
| Total debt                      | 3,172          | 2,907          | 2,819          | 3,289          | 3,603           |
| Non Current Liabilities         | 0              | 0              | 0              | 0              | 0               |
| Def tax liab. (net)             | 0              | 0              | 0              | 0              | 0               |
| <b>Total liabilities</b>        | <b>24,570</b>  | <b>21,113</b>  | <b>17,809</b>  | <b>20,581</b>  | <b>22,188</b>   |
| Gross block                     | 4,786          | 7,999          | 4,323          | 4,380          | 4,639           |
| Less: acc. Depreciation         | (486)          | (827)          | (793)          | (591)          | (606)           |
| Net block                       | 4,300          | 7,173          | 3,530          | 3,789          | 4,033           |
| Capital WIP                     | 10,026         | 1,201          | 132            | 132            | 132             |
| Net fixed assets                | 14,326         | 8,767          | 3,975          | 4,234          | 4,477           |
| Non Current Assets              | 923            | 622            | 622            | 635            | 692             |
| Investments                     | 17             | 15             | 14             | 14             | 14              |
| Inventories                     | 4,865          | 4,830          | 5,467          | 2,285          | 2,484           |
| Sundry debtors                  | 1,205          | 998            | 2,156          | 1,057          | 1,159           |
| Cash & Cash Equivalents         | 11,713         | 10,832         | 11,580         | 11,784         | 13,495          |
| Loans & advances                | 900            | 310            | 257            | 3,801          | 4,165           |
| Other current assets            | 1,412          | 779            | 2,567          | 2,474          | 2,539           |
| Trade payables                  | 4,058          | 3,576          | 4,645          | 3,213          | 3,633           |
| Other current liab.             | 9,561          | 3,898          | 6,138          | 4,331          | 7,222           |
| Provisions                      | 924            | 2,768          | 2,542          | 3,123          | 946             |
| Net current assets              | 5,551          | 7,506          | 8,702          | 10,734         | 12,040          |
| <b>Total assets</b>             | <b>24,570</b>  | <b>21,113</b>  | <b>17,809</b>  | <b>20,581</b>  | <b>22,188</b>   |
| Cashflow                        |                |                |                |                |                 |
| YE Mar (Rs mn)                  | FY19A          | FY20A          | FY21A          | FY22E          | FY23E           |
| Profit Before Tax               | 6,831          | 3,068          | 5,540          | 8,639          | 23,158          |
| Depreciation & Amortisation     | 486            | 827            | 793            | 591            | 606             |
| Net Interest                    | (1,003)        | (699)          | (1,106)        | (1,087)        | (1,648)         |
| Net Change – WC                 | (551)          | (3,318)        | 1,622          | (159)          | (1,827)         |
| Direct taxes                    | (2,066)        | (2,328)        | (2,217)        | (2,741)        | (2,551)         |
| <b>Net cash from operations</b> | <b>3,696</b>   | <b>(2,450)</b> | <b>4,633</b>   | <b>5,243</b>   | <b>17,738</b>   |
| Capital expenditure             | (2,355)        | 4,732          | 4,000          | (850)          | (850)           |
| Acquisitions, net               | 0              | 0              | 0              | 0              | 0               |
| Investments                     | 1              | 1              | (1,799)        | 0              | 0               |
| Others                          | 1,057          | 939            | 790            | 1,038          | 1,595           |
| <b>Net cash from investing</b>  | <b>(1,297)</b> | <b>5,673</b>   | <b>2,991</b>   | <b>188</b>     | <b>745</b>      |
| <b>FCF</b>                      | <b>2,399</b>   | <b>3,222</b>   | <b>7,624</b>   | <b>5,432</b>   | <b>18,483</b>   |
| Issue of share capital          | 0              | 0              | (7)            | 0              | 0               |
| Increase/(decrease) in debt     | (4)            | (2)            | 0              | 0              | 0               |
| Dividend paid                   | (4,072)        | (8,053)        | (6,076)        | (5,026)        | (16,772)        |
| Interest paid                   | (6)            | (63)           | 0              | 0              | 0               |
| Others                          | 432            | 4,013          | (793)          | (203)          | 0               |
| <b>Net cash from financing</b>  | <b>(3,650)</b> | <b>(4,104)</b> | <b>(6,876)</b> | <b>(5,228)</b> | <b>(16,772)</b> |
| Net change in Cash              | (1,251)        | (882)          | 748            | 204            | 1,711           |

Source: Company, Centrum Broking



## Disclaimer

Centrum Broking Limited ("Centrum") is a full-service, Stock Broking Company and a member of The Stock Exchange, Mumbai (BSE) and National Stock Exchange of India Ltd. (NSE). Our holding company, Centrum Capital Ltd, is an investment banker and an underwriter of securities. As a group Centrum has Investment Banking, Advisory and other business relationships with a significant percentage of the companies covered by our Research Group. Our research professionals provide important inputs into the Group's Investment Banking and other business selection processes.

Recipients of this report should assume that our Group is seeking or may seek or will seek Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/report. Our Company and Group companies and their officers, directors and employees, including the analysts and others involved in the preparation or issuance of this material and their dependants, may on the date of this report or from, time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. Centrum or its affiliates do not own 1% or more in the equity of this company. Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with recommendations/information inconsistent or different those made in this report. In reviewing this document, you should be aware that any or all of the foregoing, among other things, may give rise to or potential conflicts of interest. We and our Group may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of Centrum. Centrum or its affiliates do not make a market in the security of the company for which this report or any report was written. Further, Centrum or its affiliates did not make a market in the subject company's securities at the time that the research report was published.

This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients of Centrum. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. Centrum will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Persons who may receive this document should consider and independently evaluate whether it is suitable for his/ her/their particular circumstances and, if necessary, seek professional/financial advice. Any such person shall be responsible for conducting his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document.

The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by or on behalf of the Company, Centrum, the authors of this report or any other person that these projections or forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts.

The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Centrum does not provide tax advice to its clients, and all investors are strongly advised to consult regarding any potential investment. Centrum and its affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. Certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities give rise to substantial risk and are not suitable for all investors. Please ensure that you have read and understood the current risk disclosure documents before entering into any derivative transactions.

This report/document has been prepared by Centrum, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. Centrum has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change.

This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of Centrum. This report or any portion hereof may not be printed, sold or distributed without the written consent of Centrum.

The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither Centrum nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. By accepting this report, you agree to be bound by the foregoing limitations. No representation is made that this report is accurate or complete.



The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of Centrum Broking and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection.

This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

Centrum and its affiliates have not managed or co-managed a public offering for the subject company in the preceding twelve months. Centrum and affiliates have not received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for service in respect of public offerings, corporate finance, debt restructuring, investment banking or other advisory services in a merger/acquisition or some other sort of specific transaction.

As per the declarations given by them, Mrs. Cyndrella Carvalho, research analyst and and/or any of their family members do not serve as an officer, director or any way connected to the company/companies mentioned in this report. Further, as declared by them, they are not received any compensation from the above companies in the preceding twelve months. They do not hold any shares by them or through their relatives or in case if holds the shares then will not do any transactions in the said scrip for 30 days from the date of release such report. Our entire research professionals are our employees and are paid a salary. They do not have any other material conflict of interest of the research analyst or member of which the research analyst knows of has reason to know at the time of publication of the research report or at the time of the public appearance.

While we would endeavour to update the information herein on a reasonable basis, Centrum, its associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Centrum from doing so.

Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Centrum policies, in circumstances where Centrum is acting in an advisory capacity to this company, or any certain other circumstances.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Centrum Broking Limited or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.

#### Ratings definitions

Our ratings denote the following 12-month forecast returns:

Buy – The stock is expected to return above 15%.

Add – The stock is expected to return 5-15%.

Reduce – The stock is expected to deliver -5-+5% returns.

Sell – The stock is expected to deliver <-5% returns.

#### Glaxo SK Pharma



Source: Bloomberg

**Disclosure of Interest Statement**

|  |   |
|--|---|
| 1 Business activities of Centrum Broking Limited (CBL)   | Centrum Broking Limited (hereinafter referred to as "CBL") is a registered member of NSE (Cash, F&O and Currency Derivatives Segments), MCX-SX (Currency Derivatives Segment) and BSE (Cash segment), Depository Participant of CDSL and a SEBI registered Portfolio Manager. |
| 2 Details of Disciplinary History of CBL   | CBL has not been debarred/ suspended by SEBI or any other regulatory authority from accessing /dealing in securities market.  |
| 3 Registration status of CBL:  | CBL is registered with SEBI as a Research Analyst (SEBI Registration No. INH000001469)  |
| <b>Glaxo SK Pharma</b>   |   |
| 4 Whether Research analyst's or relatives' have any financial interest in the subject company and nature of such financial interest  | No  |
| 5 Whether Research analyst or relatives have actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the document. | No  |
| 6 Whether the research analyst or his relatives has any other material conflict of interest  | No  |
| 7 Whether research analyst has received any compensation from the subject company in the past 12 months and nature of products / services for which such compensation is received                                    | No  |
| 8 Whether the Research Analyst has received any compensation or any other benefits from the subject company or third party in connection with the research report  | No  |
| 9 Whether Research Analysts has served as an officer, director or employee of the subject company  | No  |
| 10 Whether the Research Analyst has been engaged in market making activity of the subject company.   | No  |
| 11 Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past twelve months;  | No  |
| 12 Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;                                  | No  |
| 13 Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;  | No  |

**Member (NSE and BSE). Member MSEI (Inactive)****Single SEBI Regn No.: INZ000205331****Depository Participant (DP)**

CDSL DP ID: 120 – 12200

SEBI REGD NO.: CDSL: IN-DP-CDSL-661-2012

PORTFOLIO MANAGER

SEBI REGN NO.: INP000004383

Research Analyst

SEBI Registration No. INH000001469

Mutual Fund Distributor

AMFI REGN No. ARN- 147569

**Website:** www.centrum.co.in**Investor Grievance Email ID:** investor.grievances@centrum.co.in**Compliance Officer Details:**

Ashok D Kadambi

(022) 4215 9937; Email ID: compliance@centrum.co.in

**Centrum Broking Ltd. (CIN :U67120MH1994PLC078125)****Registered Office Address**Bombay Mutual Building,  
2nd Floor, Dr. D. N. Road,  
Fort, Mumbai - 400 001**Corporate Office & Correspondence Address**Centrum House  
6th Floor, CST Road, Near Vidya Nagari Marg, Kalina, Santacruz (E), Mumbai  
400 098.  
Tel: (022) 4215 9000 Fax: +91 22 4215 9344